Thrombophilia and its impact on pregnancy

Hamostaseologie

Volumn 28, Issue 3, 2008, Pages 130-134

  Pabinger, Ingrid ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

Abortion; Fetal loss; Pre eclampsia; Pregnancy; Stillbirth; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; HEPARIN; PHOSPHOLIPID ANTIBODY; PROTHROMBIN;

ANTITHROMBIN DEFICIENCY; HUMAN; PREECLAMPSIA; PREGNANCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; THROMBOPHILIA; THROMBOSIS;

COMORBIDITY; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; THROMBOPHILIA;

EID: 46749119889     PISSN: 07209355     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1617170     Document Type: Review

References (58)

1. Bick RL. Recurrent miscarriage syndrome due to blood coagulation protein/platelet defects: prevalence, treatment and outcome results. DRW Metroplex Recurrent Miscarriage Syndrome Cooperative Group. Clin Appl Thromb Hemost 2000; 6: 115-125.
2. Clark P, Brennand J, Conkie JA et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-1170.
3. Stirling Y, Woolf L, North WR et al. Haemostasis in normal pregnancy. Thromb Haemost 1984; 52: 176-182.
4. Comp PC, Thurnau GR, Welsh J et al. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986; 68: 881-885.
5. Bonnar J, McNicol GP, Douglas AS. Fibrinolytic enzyme system and pregnancy. Br Med J 1969; 3: 387-389.
6. Beller FK, Ebert C. The coagulation and fibrinolytic enzyme system in pregnancy and in the Puerperium. Eur J Obstet Gynecol Reprod Biol 1982; 13: 177-197.
7. Sondheimer S. Abortion. Encyclopedia of Reproduction 1999; 1: 1-6.
8. Preston FE, Rosendaal FR, Walker ID et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996; 348: 913-916.
9. Rai R, Regan L, Hadley E et al. Second-trimester pregnancy loss is associated with activated C resistance. Br J Haematol 1996; 92: 489-490.
10. Sanson BJ, Friederich PW, Simioni P et al. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996; 75: 387-388.
11. Kupferminc MJ, Eldor A, Steinman N et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13.
12. Gris JC, Ripart-Neveu S, Maugard C et al. Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost 1997; 77: 1096-1103.
13. Grandone E, Margaglione M, Colaizzo D et al. Factor V Leiden is associated with repeated and recurrent unexplained fetal losses. Thromb Haemost 1997; 77: 822-824.
14. Martinelli I, Taioli E, Cetin I et al. Mutations in coagulation factors in women with unexplained late fetal loss. N Engl J Med 2000; 343: 1015-1018.
15. Younis JS, Brenner B, Ohel G et al. Activated protein C resistance and factor V Leiden mutation can be associated with first-as well as second-trimester recurrent pregnancy loss. Am J Reprod Immunol 2000; 43: 31-35.
16. Pihusch R, Buchholz T, Lohse P et al. Thrombophilic gene mutations and recurrent spontaneous abortion: prothrombin mutation increases the risk in the first trimester. Am J Reprod Immunol 2001; 46: 124-131.
17. Alonso A, Soto I, Urgelles MF et al. Acquired and inherited thrombophilia in women with unexplained fetal losses. Am J Obstet Gynecol 2002; 187: 1337-1342.
18. Rasmussen A, Ravn P. High frequency of congenital thrombophilia in women with pathological pregnancies? Acta Obstet Gynecol Scand 2004; 83: 808-817.
19. Gris JC, Quere I, Sanmarco M et al. Antiphospholipid and antiprotein syndromes in non-thrombotic, non-autoimmune women with unexplained recurrent primary early foetal loss. The Nimes Obstetricians and Haematologists Study - NOHA. Thromb Haemost 2000; 84: 228-236.
20. Rai R, Shlebak A, Cohen H et al. Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod 2001; 16: 961-965.
21. Carp H, Salomon O, Seidman D et al. Prevalence of genetic markers for thrombophilia in recurrent pregnancy loss. Hum Reprod 2002; 17: 1633-1637.
22. Dudding TE, Attia J. The association between adverse pregnancy outcomes and maternal factor V Leiden genotype: a meta-analysis. Thromb Haemost 2004; 91: 700-711.
23. Kovalevsky G, Gracia CR, Berlin JA et al. Evaluation of the association between hereditary thrombophilias and recurrent pregnancy loss: a meta-analysis. Arch Intern Med 2004; 164: 558-563.
24. Rey E, Kahn SR, David M et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-908.
25. Hashimoto K, Shizusawa Y, Shimoya K et al. The factor V Leiden mutation in Japanese couples with recurrent spontaneous abortion. Hum Reprod 1999; 14: 1872-1874.
26. Robertson L, Wu O, Langhorne P et al. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132: 171-196.
27. Lindqvist PG, Svensson PJ, Marsaal K et al. Activated protein C resistance (FV:Q506) and pregnancy. Thromb Haemost 1999; 81: 532-537.
28. Murphy RP, Donoghue C, Nallen RJ et al. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000; 20: 266-270.
29. Carp H, Dolitzky M, Inbal A. Thromboprophylaxis improves the live birth rate in women with consecutive recurrent miscarriages and hereditary thrombophilia. J Thromb Haemost 2003; 1: 433-438.
30. Kupfermine MJ, Fait G, Many A et al. Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias. Hypertens Pregnancy 2001; 20: 35-44.
31. Sanson BJ, Lensing AW, Prins MH et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81: 668-672.
32. Tzafettas J, Mamopoulos A, Anapliotis A et al. Thromboprophylaxis throughout pregnancy in women with previous history of recurrent miscarriages of unknown aetiology. Clin Exp Obstet Gynecol 2002; 29: 267-270.
33. Gris JC, Mercier E, Quere I et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-3699.
34. Saftlas AF, Olson DR, Franks AL et al. Epidemiology of preeclampsia and eclampsia in the United States, 1979-1986. Am J Obstet Gynecol 1990; 163: 460-165.
35. Brenner B, Lanir N, Thaler I. HELLP syndrome associated with factor V R506Q mutation. Br J Haematol 1996; 92: 999-1001.
36. Dizon-Townson DS, Nelson LM, Easton K et al. The factor V Leiden mutation may predispose women to severe preeclampsia. Am J Obstet Gynecol 1996; 175: 902-905.
37. Van Pampus MG, Dekker GA, Wolf H et al. High prevalence of hemostatic abnormalities in women with a history of severe preeclampsia. Am J Obstet Gynecol 1999; 180: 1146-1150.
38. Kosmas IP, Tatsioni A, Ioannidis JP. Association of Leiden mutation in factor V gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 2003; 21: 1221-1228.
39. Kosmas IP, Tatsioni A, Ioannidis JP. Association of C677T polymorphism in the methylenetetrahydrofolate reductase gene with hypertension in pregnancy and pre-eclampsia: a meta-analysis. J Hypertens 2004; 22: 1655-1662.
40. Morrison ER, Miedzybrodzka ZH, Campbell DM et al. Prothrombotic genotypes are not associated with pre-eclampsia and gestational hypertension: results from a large population-based study and systematic review. Thromb Haemost 2002; 87: 779-785.
41. Caritis S, Sibai B, Hauth J et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998; 338: 701-705.
42. Pabinger I, Grafenhofer H, Kyrle PA et al. Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism. Blood 2002; 100: 1060-1062.
43. Conard J, Horellou MH, van Dreden P et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63: 319-320.
44. Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III. protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996; 16: 742-748.
45. Tengborn L, Bergqvist D, Matzsch T et al. Recurrent thromboembolism in pregnancy and Puerperium. Is there a need for thromboprophylaxis? Am J Obstet Gynecol 1989; 160: 90-94.
46. Pabinger I, Nemes L, Rintelen C et al. Pregnancy-associated risk for venous thromboembolism and pregnancy outcome in women homozygous for factor V Leiden. Hematol J 2000; 1: 37-41.
47. Brill-Edwards P, Ginsberg JS, Gent M et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of Clot in This Pregnancy Study Group. N Engl J Med 2000; 343: 1439-1444.
48. Pabinger I, Grafenhofer H, Kaider A et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost 2005; 3: 949-954.
49. Triplett DA. Antiphospholipid antibodies and recurrent pregnancy loss. Am J Reprod Immunol 1989; 20: 52-67.
50. Meinardi JR, Middeldorp S, de Kam PJ et al. Increased risk for fetal loss in carriers of the factor V Leiden mutation. Ann Intern Med 1999; 130: 736-739.
51. Tormene D, Simioni P, Prandoni P et al. The risk of fetal loss in family members of probands with factor V Leiden mutation. Thromb Haemost 1999; 82: 1237-1239.
52. Pabinger I, Grafenhofer H, Kaider A et al. Pre-eclampsia and fetal loss in women with a history of venous thromboembolism. Arterioscler Thromb Vasc Biol 2001; 21: 874-879.
53. Vossen CY, Preston FE, Conard J et al. Hereditary thrombophilia and fetal loss: a prospective follow-up study. J Thromb Haemost 2004; 2: 592-596.
54. Rai R, Cohen H, Dave M et al. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). Br Med J 1997; 314: 253-257.
55. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-1589.
56. Farquharson RG, Quenby S, GreavesM. Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408-113.
57. Bauersachs RM, Dudenhausen J, Faridi A et al. EThIG Investigators. Risk stratification and heparin prophylaxis to prevent venous thromboembolism in pregnant women. Thromb Haemost 2007; 98: 1237-1245.
58. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106: 401-407.